Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1598

IPSC are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. For example, iPSC can be prodded into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukemia patient, or neurons to treat neurological disorders.

In late 2007, a BSCRC team of faculty, Drs. Kathrin Plath, William Lowry, Amander Clark, and April Pyle were among the first in the world to create human iPSC. At that time, science had long understood that tissue specific cells, such as skin cells or blood cells, could only create other like cells. With this groundbreaking discovery, iPSC research has quickly become the foundation for a new regenerative medicine.

Using iPSC technology our faculty have reprogrammed skin cells into active motor neurons, egg and sperm precursors, liver cells, bone precursors, and blood cells. In addition, patients with untreatable diseases such as, ALS, Rett Syndrome, Lesch-Nyhan Disease, and Duchenne’s Muscular Dystrophy donate skin cells to BSCRC scientists for iPSC reprogramming research. The generous participation of patients and their families in this research enables BSCRC scientists to study these diseases in the laboratory in the hope of developing new treatment technologies.

Read more | >

Canadian scientists have achieved a first in the study of telomerase, an essential enzyme implicated in aging and cancer.

In today’s edition of the prestigious journal Molecular Cell, scientists from Université de Montréal used advanced microscopy techniques to see single molecules of telomerase in living .

A flaw in the replication of chromosomes means that they get shorter with each . If nothing is done to correct this error, replication stops and cells go into a state called senescence, a hallmark of aging. Normally, telomerase adds extra DNA to the ends of chromosomes to prevent this problem, but as we age our bodies produce fewer of them.

Read more | >

Circa 2019

In the past decade, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Recent studies have explored various approaches to induce reprogramming from one cell type to another, including lineage-specific transcription factors-, combinatorial small molecules-, microRNAs- and embryonic microenvironment-derived exosome-mediated reprogramming. These reprogramming approaches have been proven to be technically feasible and versatile to enable re-activation of sequestered epigenetic regions, thus driving fate decisions of differentiated cells. One of the significant utilities of cancer cell reprogramming is the therapeutic potential of retrieving normal cell functions from various malignancies. However, there are several major obstacles to overcome in cancer cell reprogramming before clinical translation, including characterization of reprogramming mechanisms, improvement of reprogramming efficiency and safety, and development of delivery methods. Recently, several insights in reprogramming mechanism have been proposed, and determining progress has been achieved to promote reprogramming efficiency and feasibility, allowing it to emerge as a promising therapy against cancer in the near future. This review aims to discuss recent applications in cancer cell reprogramming, with a focus on the clinical significance and limitations of different reprogramming approaches, while summarizing vital roles played by transcription factors, small molecules, microRNAs and exosomes during the reprogramming process.

Read more | >

#BREAKING: Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19. bit.ly/3leFbzp

Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, indicating the company is on track later this month to file an emergency use application with U.S. regulators.

Monday’s announcement doesn’t mean a vaccine is imminent: This interim analysis, from an independent data monitoring board, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the U.S. and five other countries.

Pfizer Inc. did not provide any more details about those cases, and cautioned the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual.

Continue reading “Pfizer says early data signals COVID-19 vaccine is effective” | >

The ability to cancel magnetic fields has benefits in quantum technology, biomedicine, and neurology.

A team of scientists including two physicists at the University of Sussex has found a way to circumvent a 178-year old theory which means they can effectively cancel magnetic fields at a distance. They are the first to be able to do so in a way that has practical benefits.

The work is hoped to have a wide variety of applications. For example, patients with neurological disorders such as Alzheimer’s or Parkinson’s might in the future receive a more accurate diagnosis. With the ability to cancel out ‘noisy’ external magnetic fields, doctors using magnetic field scanners will be able to see more accurately what is happening in the brain.

Read more | >

The U.S. drone delivery company Zipline is getting ready to begin commercial operations in Israel next year, TheMarker has learned. The company has begun the regulatory process and is in talks with potential customers.

Zipline hopes to begin its pilot program in Israel early next year, delivering blood and medicine to hospitals in the north and south of the country. While the company has drawn up detailed plans for entering the local market, there’s no guarantee that the pilot will develop into a commercial launch of the service.

Founded in 2014, Zipline has raised around 230 million to date and has a valuation of more than $1 billion. It’s considered the most prominent player in the field: The company has operated commercial drone delivery services since 2016 and has carried out more than 70,000 deliveries.

Read more | >

Restoration of lost motor function after stroke is typically accomplished after strenuous rehabilitation therapy lasting for over months. However, new research published by a group led by Yukio Nishimura, the project leader of the Neural Prosthesis Project, Tokyo Metropolitan Institute of Medical Science showed that an artificial neural connection (ANC)*1 successfully allowed a new cortical site, previously unassociated with hand movements, to regain control of a paralyzed hand in a matter of minutes.

In this research, experimental animals regained voluntary control of a paralyzed hand about ten minutes after establishment of an ANC. Animals engaged in learning with a functional ANC showed variable levels of input signals provided by the cerebral cortex*2 as hand movement improved. Specifically, the activated area of the cortex became more focused as control of hand movements improved.

Through this training of various areas of the cerebral cortex, the research team successfully imparted a new ability to control paralyzed hands via an ANC, even if those areas were not involved in hand control prior to the stroke. Examples of such regions include areas of the cortex that controls the movement of other body parts such as the face or shoulder, and even the somatosensory cortex, which is responsible for tactile and proprioception processing and is normally not associated with motor control. This finding suggests that an ANC can impart new motor control functions to any cortical region.

Read more | >